Skip to main content
Premium Trial:

Request an Annual Quote

Innovir Labs Is Awarded Patents Covering Use of Oligozymes in Research

Premium

NEW YORK--Innovir Laborato ries here announced last month that it has gained additional US patent rights covering the use of oligozymes in pharmaceutical and genomic research, with four patent applications being allowed and two new patents issued. Innovir already holds three issued patents, eight allowed patent applications, and 20 patent pending applications for oligozyme-based technology.

In addition, the company has corresponding foreign patent rights and has exclusively licensed some related patents from Yale University. "These patents further enhance Innovir's ability to harness oligozymes' strong potential for defining which genes cause certain diseases and which are good targets for drug research," commented Thomas Sharpe, the company's president and CEO. Innovir is a majority-owned subsidiary of VIMRX Pharmaceuticals.

Filed under

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.